Zymeworks Inc. ZYME

Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assetsYUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRRZymeworks to retain existing commercial organization supporting YUPELRI hospital promotionThe Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 mill

Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks,

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Zii

Why Zymeworks Stock Is Back in Focus After FDA Approval Zymeworks (ZYME) moved into the spotlight after the FDA approved zanidatamab for first line HER2 positive gastroesophageal adenocarcinoma, putting fresh attention on what this decision might imply for future revenue potential. Against this backdrop, Zymeworks has seen momentum build, with a 30 day share price return of 28.31% and a 90 day gain of 15.44%. The 1 year total shareholder return of 95.49% and very large 3 year total...

Zymeworks stock has delivered very strong returns over the past three years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Recent gains and optimism around its HER2-targeting therapy are now being weighed against signals that point to limited valuation cushion at today’s levels. Zymeworks has returned about 301% over the past three years, which puts extra focus on whether recent gains already reflect much of the good...

SJM raised its annual outlook following a quarterly earnings beat, while ZYME gained on price-target hikes tied to Ziihera’s FDA approval.

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA. Ziihera, or zanidatamab, is approved in combination with tisl

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.

The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.

Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line GEASecond FDA approval for zanidatamab in less than two years further validates Zymeworks’ proprietary Azymetric™ bispecific antibody platform and internal discovery engineFDA approval triggers a $250 million milestone payment from Jazz Pharmaceuticals, with Zymeworks remaining eligible for up to

Zymeworks (NASDAQ:ZYME) shares climbed nearly 4. 0% in pre-market trading as investors positioned themselves ahead of an important U.

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (

Zymeworks CEO Kenneth Galbraith speaks about the company’s progress for in Q2 2026 August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestonesAcquisition of Theravance Biopharma, Inc. expected to close in 2H 2026, adding durable commercial cash flows and expanding Zymeworks' diversified revenue baseContinued advancement of R&D pipeline across wholly-owned a